Status:
COMPLETED
Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.
Lead Sponsor:
Institut de cancérologie Strasbourg Europe
Collaborating Sponsors:
ICube Laboratory
Conditions:
Brain Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
With 18F-FDG PET, we have few atlases of normality allowing the realization of objective quantitative analyses. An atlas of normality is a probabilistic atlas of normal FDG uptake from a representativ...
Detailed Description
This is a prospective, monocentric, non-randomized study, with no direct individual benefit since it involved healthy volunteers.
Eligibility Criteria
Inclusion
- Male or female aged 20 to 50
- Absence of any history or cardiovascular, neurological or psychiatric deficit
- Signed the informed consent
Exclusion
- Contraindication to the realization of an MRI or PET and to the injection of 18F-FDG
- People using a pacemaker or insulin pump
- People wearing a metal prosthesis or an intracerebral clip
- People with intraocular metal splinters
- People with a pathology considered incompatible for the production of the atlas according to the investigator
- Pregnant women and breastfeeding women
- Subject in period of exclusion.
Key Trial Info
Start Date :
August 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 23 2023
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT05355857
Start Date
August 10 2022
End Date
March 23 2023
Last Update
April 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de cancérologie Strasbourg Europe
Strasbourg, France